49 research outputs found
Regulation of Corticotropin-Releasing Factor-Binding Protein Expression in Amygdalar Neuronal Cultures
Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/73102/1/j.1365-2826.1999.00413.x.pd
Differential effects of TRPV1 receptor ligands against nicotine-induced depression-like behaviors
Exposure to an Antisense Oligonucleotide Decreases CorticotropinâReleasing Factor Receptor Binding in Rat Pituitary Cultures
: Corticotropinâreleasing factor (CRF) appears to integrate the endocrine, autonomic, immunologic, and behavioral responses of mammals to stress. To investigate further the role of CRF in the CNS, we have begun investigating the usefulness of âantisense knockdownâ strategies directed against the CRF receptor using rat anterior pituitary gland primary cell cultures. The 15âmer antisense (5âČ CTGâCGGâGCGâCCGâTCC 3âČ) and âscrambledâ control (5âČ CGTâCCGâCGCâGCTâGCG 3âČ) oligonucleotides were synthesized based on the rat CRF receptor sequence just downstream of the initiation codon. In each of four separate experiments, exposure to 10 ”mol/L of antisense oligonucleotide for 40â67 h resulted in significant (17â36%) decreases in 125Iâovine CRF binding to pituitary cells as compared with either control (no oligonucleotide) or 10 ”mol/L of âscrambledâ oligonucleotide. Moreover, compared with scrambled oligonucleotide, exposure to 10 ”mol/L of antisense oligonucleotide, which produced a 22% decrease in CRF receptor binding, also resulted in a significant attenuation of the adrenocorticotrophic hormone response following a 30âmin challenge with 100 pmol/L of CRF. Thus, CRF receptor antisense oligonucleotides apparently reduce functional expression of CRF receptors. This technique may be useful in studying the kinetics of CRF receptor production and the physiological functions of CRF receptors within the CNS
Recommended from our members
Corticotropin-releasing factor is secreted in the BE(2)-C neuroblastoma cell and is responsive to forskolin
The BE(2)-C human neuroblastoma has been shown to express corticotropin-releasing factor (CRF) messenger RNA. In this study, BE(2)-C cells were treated 5 days with 5 ÎŒM retinoic acid. Cell extracts were also applied onto a C18 Vydac column and fractions were assayed for CRF-like immunoreactivity (CRF-LI) which coincided in time of elution with oxidized or non-oxidized CRF synthetic CRF standard. With forskolin treatment, secretion media and cell extract CRF-LI increased in a concentration-dependent fashion. Thus, this cell line synthesizes and secretes CRF and is a good model for studying CRF regulation
Recommended from our members
The BE (2)-M17 neuroblastoma cell line synthesizes and secretes corticotropin-releasing factor
The BE (2)-M17 human neuroblastoma has previously been show to express corticotropin-releasing factor (CRF) mRNA following retinoic acid treatment. It is demonstrated in this report that both cell extracts and cell incubation medium of retinoic acid-treated BE (2)-M17 cells were shown to contain CRF-like immunoreactivity (CRF-LI) by RIA. CRF-LI secretion and content were also dose-dependently increased by forskolin. In addition, cell extracts were applied to a C
18 Vydac column and peak CRF-LI from the collected fractions was shown to coincide in time of elution with peak immunoreactivity seen with oxidized synthetic CRF standard. Thus, in containing the CRF peptide, the BE (2)-M17 cells are useful models for further study of CRF cellular and genetic regulation
Recommended from our members
Regulation of CorticotropinâReleasing Factor Secretion and Synthesis in the Human Neuroblastoma Clonesâ BE(2)âM17 and BE(2)âC
The BE(2)âM17 and BE(2)âC human neuroblastoma cell lines have been shown to synthesize and secrete corticotropinâreleasing factor (CRF) following retinoic acid treatment. It has been demonstrated that CRF secretion and intracellular synthesis increases in response to forskolin treatment. In this report, we have further characterized these cells in response to protein kinase C activators, dexamethasone, interleukinâ1x, as well as various neurotransmitters and peptides. Nanomolar concentrations of the phorbol esterâphorbol 12 myristate 13âacetate (TPA), increased intracellular CRF content in both cell lines while increasing secretion only in the BE(2)âM17 cell. Nanomolar concentrations of dexamethasone were not able to alter basal levels of secretion and content in either cell type. However, in the BE(2)âMl7 cell but not the BE(2)âC cell, the same concentrations of dexamethasone added to 30 ÎŒM forskolin augmented levels of CRF secretion and content. Likewise, the same augmented response in CRF secretion and content was seen only in the BE(2)âM17 cell line when nanomolar concentrations of dexamethasone were added to 20 nM TPA. Furthermore, only in the BE(2)âM17 cell line were micromolar levels of the biogenic amine serotonin able to increase levels of CRF secretion and content. No effects on CRF in both cell lines were demonstrable with picomolar levels of interleukinâ10: as well as micromolar levels of acetylcholine, norepinephrine, arginineâvasopressin, oxytocin, and angiotensinâII. The potential usefulness of these cells as models of central nervous system or placental CRFâcontaining neurons is discussed